There are very few data available regarding the pattern of first metastases in resected mucosal melanomas (MMs) as well as the response of advanced MM to cytotoxic therapy. A retrospective, single-institution cohort was assembled of all patients with advanced/unresectable MM between 1995 and 2012 who had received systemic therapy with available imaging (N = 81). Responses to first-line and second-line systemic therapy were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The relationship between response, overall survival, and clinical covariates was investigated using Cox proportional hazards regression. Primary sites included anorectal (N = 31, 38%), vulvovaginal (N = 28, 35%), head and neck (N = 21, 26%), and gallbladder (N = 1, 1%) mucosa. Seven percent of patients had their first relapse in the brain. Cytotoxic therapy represented 82 and 51% of first-line and second-line regimens. The best response achieved in the first-line setting was similar for single-agent [10%; 95% confidence interval (CI): 1-32%] and combination alkylator therapy (8%; 95% CI: 2-21%). Median overall survival from first-line treatment was 10.3 months (95% CI: 8.7-13.9 months). Patients with elevated lactic dehydrogenase [hazard ratio (HR): 1.87, 95% CI: 1.10-3.19, P = 0.020] and Eastern Cooperative Oncology Group performance status 1-2 (HR: 1.69, 95% CI: 1.05-2.72, P = 0.030) had a higher risk of death, whereas patients with 12-week objective responses had a lower risk of death (HR: 0.12, 95% CI: 0.04-0.41, P < 0.001). Cytotoxic systemic therapy has modest activity in advanced/unresectable MM, belying its adjuvant benefit. Patients whose tumors have an objective response to therapy have a lower probability of death. Brain imaging should be considered in routine surveillance. Melanoma Res 27:57-64
Introduction
Malignant melanoma is a heterogenous group of melanocytic neoplasms diagnosed in ∼ 76 000 people annually in the USA [1] . Mucosal melanomas (MMs) comprise 1-2% of all melanomas in the USA and arise from non-hair-bearing mucosal surfaces of the body, most commonly the head and neck, anorectal, or vulvovaginal regions [2] . MM is clinically and genetically distinct from cutaneous melanoma (CM) [3, 4] . Patients diagnosed with MM tend to be older than those with cutaneous or uveal primary sites, and their stage-matched prognosis is poorer [5, 6] . A retrospective review of survival from the time of metastasis in 2920 patients with melanoma of various primary sites demonstrated that those with MM lived a median [95% confidence interval (CI)] of 9.1 (7.6-9.8) versus 13.4 (11.6-15.6) and 11.7 (11.2-12.6) months for those with uveal and cutaneous disease, respectively [6] . It is not clear whether clinical factors such as site of first metastasis or a lower response to systemic therapy influence this poorer prognosis.
The most rigorous MM therapy study to date was a large, single-center randomized phase 2 trial that enrolled 189 patients with resected MM in a 1 : 1 : 1 ratio to observation, adjuvant interferon α, or adjuvant cisplatin plus temozolomide [7] . Patients receiving adjuvant cisplatin plus temozolomide or high-dose interferon had a significant improvement in overall survival (OS) (48.7 vs. 40.4 vs. 21.2 months, respectively; P < 0.01 for both comparisons). All patients on the observation arm had a recurrence within 2 years, and 75% had a recurrence either regionally or in a distant site [7] .
Given the significant benefit of adjuvant therapy with cytotoxic agents and interferon, there is a need to document the activity of cytotoxic therapy in the advanced setting. To our knowledge, there are only four published retrospective series reporting response of MM to cytotoxic or biochemotherapy. The largest included 28 patients receiving dacarbazine-based chemotherapy and reported a similar objective response rate (ORR) between noncutaneous melanoma and CM of 20 and 30%, respectively [8] . The other studies reported responses in 7/13 (54%) head and neck MM, 8/18 (44%) anorectal MM, and 4/11 (36%) vulvovaginal MM with biochemotherapy, which combines cytotoxic agents such as cisplatin, vinblastine, and dacarbazine (CVD) with immunomodulatory therapy such as interferon α and/or interleukin-2 [9] [10] [11] .
Considering the poor prognosis for patients with MM, the magnitude of OS benefit with cytotoxic therapy, and the relative paucity of published data, we sought to assess the patterns of first metastasis, response rates, and OS for patients with MM treated with any systemic agents at our institution. CT and/or MRIs were collected at baseline and during the course of treatment for advanced or unresectable disease. Initial sites of metastatic disease were identified using radiographic or pathologic reports and were categorized by organ system. Multiple nodules in an organ were counted only once. Responses to first-line and second-line regimens were determined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by radiologists (M.J.B. and R.A.L.) blinded to treatment.
Patients and methods
Patients with metastatic disease were staged using American Joint Committee on Cancer seventh ed. guidelines [12] for CM (M1a, M1b, or M1c). Therapies were categorized into the following groups: single-agent alkylator (e.g. temozolomide or dacarbazine), combination alkylator [e.g. cisplatin, vinblastine and temozolomide (CVT)], nonalkylating cytotoxic, immunotherapy, biochemotherapy, targeted agents, and others.
Statistical analyses
Patient characteristics were summarized using medians and ranges for continuous variables and frequencies and percentage for categorical variables. Differences between site and adjuvant therapy rates were tested using Fisher's exact test. A 12-week response rate was defined as partial response (PR) or complete response (CR) using RECIST 1.1 by 12 weeks after the commencement of line 1 systemic therapy. For all response proportions, the percentage of response was provided along with exact 95% CIs.
Overall best response (BR) was defined as PR or CR using RECIST 1.1 during any point of the chemotherapy regimen. BR was measured separately for each line of therapy. Patients without scans during the duration of therapy were excluded from the analysis. A 24-week disease control rate (DCR) was defined as RECIST 1.1 PR, CR, or stable disease at or after 24 weeks of treatment in all patients evaluable for response. If a patient stopped or changed regimens before 24 weeks or did not have a scan available, they were considered not controlled.
OS was defined as the time interval between chemotherapy line 1 commencement and death or last followup. Patients alive at the last follow-up were censored. Factors associated with OS were evaluated using Cox proportional hazards regression and a 12-week response was modeled as a time-dependent covariate. OS stratified by response rate was plotted by Kaplan-Meier methods landmarked at 12 weeks. P values less than 0.05 were considered statistically significant. All analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina, USA) and R 3.1.1 (The R Foundation, Vienna, Austria).
Results

Patient characteristics
Patient characteristics and demographics are shown in Table 1 . Overall, 81 patients met the inclusion criteria.
The median age at diagnosis was 63 years (range: 33-89 years). Seventy-three percent (59/81) of patients were female and 82% (66/81) were white. Thirty-eight percent (31/81) had disease arising from the anorectal mucosa, 26% (21/81) from the head and neck, 35% (28/81) from the vulvovaginal mucosa, and 1% (1/81) from the gallbladder. Eighty-four percent (68/81) underwent resection of the primary disease.
Mutation status of KIT, BRAF, and NRAS genes was available for a subset of tumors. In total, 9/43 (21%) were found to harbor KIT mutations, with eight affecting exon 11 (six L576P, one V560D, and one deletion) and one affecting exon 13 (V654A). Three of 38 (8%) harbored BRAF mutations, with two D594 missense mutations and one T599I mutation identified. Five of thirty-six (14%) harbored NRAS mutations, with three Q61 mutations and two G12D mutations observed.
Pattern of initial metastases
At the time of the first nonadjuvant systemic treatment, 84% of patients had metastatic disease identified on imaging and 16% had locally advanced unresectable disease. LDH was elevated in 33% of cases.
At the initial diagnosis of metastatic disease, 143 organ sites were involved (Fig. 1) . Forty-eight percent of patients had metastasis limited to one organ site. The most common sites of initial metastasis were the liver (57%), lung (41%), nonregional LN (38%), and soft tissue (22%). Bone metastases were observed in nine (12%) cases: six from head and neck, three from anorectal, and none from vulvovaginal MM. Brain metastases were relatively uncommon, but were observed as an initial metastatic site in five (7%) cases, including two vulvovaginal (one vulvar, one vaginal) melanomas and one each from the rectal, nasal cavity, and gallbladder regions.
Treatment
In total, 74 and 43 patients were evaluable for response to first-line and second-line systemic therapy, respectively (Table 2) . Sixty-one (82%) first-line regimens and Cytotoxic therapy in advanced mucosal melanoma Shoushtari et al. 59
22 (51%) second-line regimens included cytotoxic agents. Of these, 38 (62%) and 15 (68%), respectively, were combination alkylator regimens; 20 (33%) and two (5%), respectively, were single-agent alkylators; and three (5%) and five (12%), respectively, were nonalkylator regimens.
Immune-based therapy was utilized in seven (10%) firstline and 13 (30%) second-line regimens, with the most common agent being ipilimumab (N = 4 and 6, respectively). Three patients received PD-1 inhibitors, all in the second-line setting (N = 2 nivolumab; N = 1 pembrolizumab). Targeted therapy was given to four (5%) patients as first-line therapy and to six (14%) patients as second-line therapy. Imatinib (N = 3 for both first-line and second-line) and nilotinib (N = 2 for second-line) were the most common targeted agents. Circos plot of all initial metastatic sites (n = 143) for 76 patients. The 143 sites are broken down by the primary site on the left half of the circle and the metastatic organ on the right half, with the segments representing the relative abundance of metastases by primary site and destination. Ribbons connect the primary site with the metastatic organ system, with the color corresponding to the primary site associated with that colored segment (e.g. anorectal, blue) and the width denoting the number of cases that metastasized to that site (e.g. anorectal spread to liver, n = 16). Relative percentages of spread are represented on the outer segments; for example, 36% of anorectal metastases were to the liver (red, 11 o'clock) and 67% of bone metastases originated from the head and neck (purple, near 6 o'clock). CVD, cisplatin, vinblastine, and dacarbazine; CVT, cisplatin, vinblastine and temozolomide; IFNα, interferon α; IL, interleukin. Table 3 Overall best response and disease control rate by type of therapy and melanoma primary site 3-24%) for patients with liver metastases and 20% (6/30, 95% CI: 8-39%) for those without. On the basis of cutaneous American Joint Committee on Cancer M staging, response was 11% (5/47; 95% CI: 4-23%) for M1c, 33% (5/15; 95% CI: 12-62%) for M1a/M1b, and 0% (0/12; 95% CI: 0-26%) for M0. BR was 16% (3/19; 95% CI: 3-40%) for patients who received adjuvant therapy, 11% (5/44; 95% CI: 4-25%) for patients who did not, and 18% (2/11; 95 CI: 2-52%) for patients who were never free of disease.
Overall survival
Median OS from initiation of first-line treatment was 10.3 months (95% CI: 8.7-13.9 months). OS did not differ by melanoma site (Fig. 2) , treatment in the first-line setting, sex, race, stage, or age (P = 0.10-0.94). However, patients with elevated LDH [hazard ratio (HR): 1.87, 95% CI: 1.10-3.19, P = 0.020] and ECOG 1-2 (HR: 1.69, 95% CI: 1.05-2.72, P = 0.030) had a higher risk of death. Patients with objective responses by 12 weeks had significantly lower risk of death (HR: 0.12, 95% CI: 0.04-0.41, P < 0.001) ( Table 4) .
Discussion
To our knowledge, this historical series is the largest to report the effects of cytotoxic therapy in patients with MM. Reporting the initial sites of metastases provides guidance for metastatic surveillance in the postoperative setting. Regardless of primary site, the most common initial sites of metastasis were the lungs, liver, and nonregional lymph nodes. The rate of brain involvement as an initial site of metastasis was 7%, and no primary site was free of risk. Given these data, any surveillance imaging for MM should include the chest, abdomen, and pelvis, and brain imaging could be justified.
Overall, the BR and 24-week DCRs to systemic therapy were modest in both the first-line and second-line settings and are lower than those seen in cutaneous disease. Notably, this historical cohort was weighted toward cytotoxic therapy. Alkylator-based cytotoxic therapy resulted in first-line ORRs of ∼ 10%. This ORR is lower than the 16-27% reported in CM [13, 14] and somewhat lower than the 20% ORR for MM reported in a smaller cohort [8] . This analysis provides an estimate for a historical 'nonpromising' response rate that can be used to power future clinical trials in MM. Furthermore, this modest activity of cytotoxic therapy in the advanced setting belies the magnitude of survival benefit seen in the adjuvant randomized trial of MM [7] , especially given the fact that an adjuvant trial of dacarbazine did not benefit patients in CM [15] . A second, multicenter randomized trial is needed to confirm the benefit of adjuvant cytotoxic therapy for patients with MM. Overall survival (OS) from initiation of first systemic treatment by primary site. OS was 10.3 months (95% confidence interval: 8.7-13.9 months). There was no significant difference in median OS for tumors arising from the anorectal, head and neck, and vulvovaginal regions (P = 0.57, log-rank test). MM, mucosal melanoma.
We did not detect a significant association between response and single-agent versus combination cytotoxic therapy. This analysis could not control for selection bias because of its retrospective design, and the sample size limited our ability to control for other factors in the response analysis. This study, nonetheless, represents the largest cohort of patients to date receiving these therapies. Given the historically higher toxicity rates of combination cytotoxic regimens [16] and the lack of difference in response rate in this cohort, single agents such as temozolomide or dacarbazine may be preferable for patients with MM who lack other clinical trial options.
With regard to immune checkpoint blockade, the 10 patients receiving ipilimumab in this report were part of a previously reported cohort [17] that reported a 7% response rate. Only three patients in our report received anti-PD-1 agents, and none derived clinical benefit. Thus, this analysis did not provide additional insight into clinical activity with these standard first-line agents that recently demonstrated ORRs of 23% with nivolumab (95% CI: 15-34%) and 37% with nivolumab plus ipilimumab (95% CI: 22-55%) [18] .
OS from the time of initiation of systemic therapy was less than 1 year in this cohort, with no significant differences between MM primary sites. Increased LDH and poor ECOG performance status predicted a higher risk of death, consistent with findings in CM. Although the class of cytotoxic therapy was not associated with improved OS, the risk of death was significantly lower in the select group of patients whose tumors have an objective 12-week response to systemic therapy compared with those whose tumors did not respond (HR: 0.12, 95% CI: 0.04-0.41). Further investigation is needed to identify the molecular and/or immunologic mechanisms of MM initiation and progression that will allow us to better select immune-based and other treatments that will benefit these patients. The single patient with a gallbladder primary was excluded from statistical analyses where site was a covariate. b Modeled using time-dependent covariate.
